Company Overview

Legend Biotech Corporation is a clinical-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of cell therapies for oncology and other indications. The company operates primarily in the biotechnology and biopharmaceutical industries, with a strategic emphasis on chimeric antigen receptor T-cell (CAR-T) therapies. Its most significant commercial asset is ciltacabtagene autoleucel, marketed as CARVYKTI, a BCMA-targeted CAR-T therapy for multiple myeloma developed in collaboration with Johnson & Johnson Innovative Medicine through Janssen Biotech, Inc. The company generates revenue primarily through collaboration agreements, milestone payments, manufacturing activities, and product-related revenue associated with CARVYKTI commercialization.

Legend Biotech was founded in 2014 as a subsidiary of GenScript Biotech Corporation and later became independently listed on Nasdaq under the ticker LEGN in 2020. The company evolved from a broader life sciences and genomic engineering ecosystem into a focused cell therapy developer with integrated research, clinical development, and manufacturing capabilities. Its strategic positioning is supported by proprietary cell therapy technologies, vertically integrated manufacturing infrastructure, and a partnership model that leverages the global commercialization capabilities of Johnson & Johnson.

Business Operations

Legend Biotech’s operations are centered on the development and commercialization of autologous CAR-T therapies. The company’s primary operating activities include research and development, clinical trials, manufacturing, and commercialization support for cell therapies targeting hematologic malignancies and solid tumors. Its lead product, CARVYKTI, represents the company’s primary commercial revenue driver and is approved in multiple jurisdictions for the treatment of relapsed or refractory multiple myeloma. The company also maintains a pipeline of earlier-stage oncology and autoimmune disease programs utilizing cell therapy platforms.

The company operates manufacturing and research facilities across the United States, China, and Europe, including large-scale cell therapy manufacturing infrastructure in New Jersey and Belgium. Legend Biotech maintains strategic partnerships with Janssen Biotech, Inc., which is responsible for portions of global commercialization activities related to CARVYKTI. The company also benefits from historical ties to GenScript Biotech Corporation, which remains a significant shareholder and strategic affiliate. Revenue generation is tied to collaboration agreements, royalty structures, manufacturing services, and shared commercialization economics under its partnership arrangements.

Strategic Position & Investments

Legend Biotech’s strategic direction is focused on expanding the commercial reach of CARVYKTI, advancing next-generation cell therapies, and increasing manufacturing scale to support global demand. The company has invested significantly in manufacturing capacity expansion and process optimization to improve production efficiency and treatment accessibility. Its collaboration with Johnson & Johnson has provided financial support, clinical development resources, and global market access, positioning the company competitively within the rapidly expanding CAR-T therapy market.

In addition to CARVYKTI lifecycle expansion efforts, Legend Biotech continues to invest in pipeline programs targeting solid tumors and autoimmune diseases. The company has pursued research initiatives involving novel CAR constructs, dual-targeting technologies, and allogeneic approaches intended to broaden the applicability of cell therapies. Strategic investments have included facility development in the United States and Europe, as well as continued investment in proprietary manufacturing technologies intended to enhance scalability and reduce turnaround times.

Geographic Footprint

Legend Biotech maintains a global operational footprint with headquarters in Somerset, New Jersey, and significant operational activities in China, the United States, and Europe. The company conducts clinical development and commercial operations across multiple international markets, including North America, Europe, and parts of Asia-Pacific. Its manufacturing network supports multinational distribution and regulatory compliance requirements associated with autologous cell therapies.

The company’s international presence is reinforced through its collaboration with Johnson & Johnson, enabling broader commercialization access in major pharmaceutical markets. Manufacturing facilities and research operations in Belgium, China, and the United States provide operational redundancy and regional production support. Legend Biotech’s therapies have obtained regulatory approvals or commercial presence in several jurisdictions, including the United States and European Union member states.

Leadership & Governance

Legend Biotech’s leadership team combines biotechnology research expertise, pharmaceutical commercialization experience, and operational management capabilities. The company’s governance structure includes executives with backgrounds in oncology drug development, manufacturing operations, finance, and global strategy. The company has emphasized long-term investment in innovation, manufacturing integration, and global expansion as part of its strategic vision.

Key executives include:

• Ying Huang – Chief Executive Officer
• Wenjun Wang – Chief Financial Officer
• Frank Zhang – Vice Chairman of the Board
• Juan Ruiz – Chief Medical Officer
• James Zhao – Chief Strategy Officer
• Lepu Zhang – Chief Technical Officer

The company’s leadership philosophy has emphasized scientific innovation, global collaboration, and scalable commercialization of advanced cell therapies. Public disclosures in SEC filings, annual reports, and investor presentations consistently identify manufacturing expansion, clinical execution, and strategic partnerships as central priorities for long-term growth.